<DOC>
	<DOCNO>NCT00149019</DOCNO>
	<brief_summary>Patients resistant metastatic solid tumor fail conventional modality eligible immunotherapy bispecific antibody . First step : NST Second step : Patients tumor cell express positive Her-2Neu and/or EpCAM residual recurrent disease follow NST candidate donor lymphocytes immunotherapy use bispecific antibody . Patients match donor available , express positive Her-2Neu and/or EpCAM tumor cell , eligible donor mismatch lymphocyte use in-vitro rIL-2 activate allogeneic lymphocyte target tumor bispecific antibody , Her-2Neu and/or EpCAM .</brief_summary>
	<brief_title>Immunotherapy Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies .</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Patients metastatic solid tumor express Her2/Neu EpCAM , available match donor NST . Patients metastatic solid tumor expect cured fail available conventional modality , age &gt; 18 , upper age limit . Patients metastatic breast cancer fail treatment Herceptin . Patients metastatic cancer cell express Her2/Neu EpCAM . Patients evidence disease follow allogeneic stem cell transplantation tumor cell express Her2/Neu EpCAM . Karnofsky performance status &gt; 60 % Life expectancy &gt; 3 month , able ass response . Patients fulfil . Patients active ongoing infection may endanger life , whenever immunosuppression may counterindicated . Pregnant lactating woman . Patients positive HIV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>